レポート概要

本レポートは、世界のメタボリックシンドローム産業の市場細分化の観点から、2018年から2022年の過去期間、2023年の推定期間、2024年から2028年の予測期間における、適応症別（インスリン抵抗性症候群、高コレステロール血症、肥満症候群、非アルコール性脂肪肝炎、その他の適応症）、分子タイプ別（低分子、タンパク質、RNA/DNA、その他の分子）、投与経路別（経口、皮下、その他のROA）の分析を提供します。

本調査はグローバルな内容で、南北アメリカ（アメリカ、カナダ、その他の地域）、ヨーロッパ（フランス、イギリス、イタリア、スペイン、ドイツ、その他の地域）、アジア太平洋地域（中国、日本、インド、その他の地域）、中東・アフリカの市場を詳細に分析したものです。さらに、市場規模、年間の成長と潜在的な分析、市場プレイヤーの競争調査、投資機会、戦略的推奨事項などのデータを提供します。

また、市場の成長指標、抑制要因、需給リスク、その他の重要な統計データを調べるとともに、市場の進化に関連する現在および将来の市場動向についても十分に評価しています。

メタボリックシンドロームの世界市場は、2021年の225億米ドルから2028年末までに289億米ドルを生み出すと予想されています。メタボリックシンドロームは、心血管疾患、2型糖尿病、その他の主要な健康問題のリスクを高める、一連の代謝異常の連鎖を特徴とする複雑な疾患です。これは公衆衛生に重大な影響を与える世界的な健康問題です。中枢性肥満、高血圧、脂質異常症（脂質プロファイルの異常）、およびグルコース代謝の低下は、メタボリックシンドロームの重要な要素です。2024年から2028年の予測期間中に、世界のメタボリックシンドローム市場は46.30％のCAGRで拡大すると予想されます。

また、ヘルスケア分野がより予防的でカスタマイズされたアプローチに移行するにつれ、メタボリックシンドロームに関連する課題のリスクを低減するために、早期発見と管理が重視されるようになってきています。このようなパターンは、診断検査、治療オプション、デジタルヘルスソリューションの需要を促進すると思われます。

各社は、メタボリックシンドロームの多くの側面に同時に対処する新規薬剤の創出に取り組んでいます。この戦略では、複数の薬剤を使用する必要性を減らしながら、患者の転帰を向上させることを目指しています。さらに、ウェアラブルガジェットやモバイルアプリケーションなどの技術的進歩により、個人が自分の健康指標をモニタリングし、体調をうまく管理できるように進化しています。

適応症別では、インスリン抵抗性症候群が市場で最大シェアを占めています。インスリン抵抗性メタボリックシンドロームの治療薬の世界市場は、糖尿病の有病率の上昇を背景に、今後数年間で拡大すると予想されます。

また、本調査では、業界の競合状況や、Novo Nordisk社、Eli Lilly and Company社、武田薬品工業（Takeda Pharmaceutical）社、Sanofi社、AstraZeneca社、Amgen社、Merck Co., Inc社、Johnson & Johnson社、Pfizer社、Abbott社といったメタボリックシンドロームの世界市場における主要企業のプロファイルを紹介しています。企業プロファイリングには、事業概要、医薬分子タイプ、その他の製品、主要財務情報、最近のイベントや開発などの重要な情報が含まれています。全体として、本レポートは、世界のメタボリックシンドローム市場の詳細な概要を提供し、業界コンサルタント、機器メーカー、拡大機会を探している既存プレイヤー、機会を探している新規プレイヤー、その他の関係者が、現在および予想される将来のトレンドと市場中心の戦略を調整する際に役立つでしょう。

調査範囲

• 本レポートは、メタボリックシンドローム市場を金額（USD 100万）別に分析します。
• 本レポートは、2018年から2021年の過去期間、2023年の推定年、2024年から2028年の予測期間におけるメタボリックシンドローム市場の分析を提供します。
• 本レポートは、メタボリックシンドローム市場を適応症別（インスリン抵抗性症候群、高コレステロール血症、肥満症候群、非アルコール性脂肪性肝炎、その他の適応症）に分析します。
• 本レポートは、分子タイプ別（低分子、タンパク質、RNA/DNA、その他の分子）にメタボリックシンドローム市場を分析します。
• 本レポートは、投与経路別（経口、皮下、その他のROA）にメタボリックシンドローム市場を分析します。
• メタボリックシンドロームの世界市場は、アメリカ、カナダ、イギリス、ドイツ、フランス、イタリア、スペイン、中国、インド、日本などの国別に分析されています。
• 本レポートの主要な洞察は、SWOTおよびポーターのファイブフォース分析のフレームワークを通じて提示されています。また、市場の魅力は、地域別、メタボリックシンドロームタイプ別、メタボリックシンドローム形態別、販売チャネル別に提示されています。
• また、業界の主要な機会、動向、推進要因、課題が分析されています。
• 本レポートは以下の主要企業の競合他社の動向、戦略、M&A、新製品開発などを追跡しています。
  ➣ 主要企業
  　　◇ Novo Nordisk
  　　◇ Eli Lilly and Company
  　　◇ 武田製薬工業（Takeda Pharmaceutical）
  　　◇ Sanofi, AstraZeneca
  　　◇ Amgen,Merck Co., Inc.
  　　◇ Johnson & Johnson
  　　◇ Pfizer
  　　◇ Abbott

  レポート詳細

  目次

  Table of Contents

  1. Market Background
  1.1 Scope and Product Outlook
  1.2 Executive Summary
  1.3 Research Methodology

  2. Strategic Recommendations

  3. Global Metabolic Syndrome Market: Historic and Forecast (2018-2028)
  3.1 Impact Analysis of Macro Economic Factors on Metabolic Syndrome Market
  3.2 Impact of COVID-19 on Metabolic Syndrome Market
  3.3 Global Metabolic Syndrome Market: Ecosystem Analysis
  3.3.1 Metabolic Syndrome Fact Sheet
  3.3.2 Pipeline Analysis of Metabolic Syndrome Therapeutics
  3.3.3 Global Obesity Statistics 2022, in Millions
  3.3.4 Top marketed Metabolic Syndrome Therapeutics by NPV, USDm
  3.3.5 Top pipeline Metabolic Syndrome Therapeutics by NPV, in USD Millions
  3.4 Global Metabolic Syndrome Market: Dashboard
  3.5 Global Metabolic Syndrome Market: Market Value Assessment, 2018-2028 (USD Million)
  3.6 Global Metabolic Syndrome Market Segmentation: By Indication
  3.6.1 Global Metabolic Syndrome Market, By Indication Type Overview
  3.6.2 Global Metabolic Syndrome Market Size, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  3.6.3 Global Metabolic Syndrome Market Size, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)
  3.6.4 Global Metabolic Syndrome Market Size, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  3.6.5 Global Metabolic Syndrome Market Size, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)
  3.6.6 Global Metabolic Syndrome Market Size, By Other Indications, By Value, 2018H-2028F (USD Million & CAGR)
  3.7 Global Metabolic Syndrome Market Segmentation: By Molecule Type
  3.7.1 Global Metabolic Syndrome Market, By Molecule Type Overview
  3.7.2 Global Metabolic Syndrome Market Size, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)
  3.7.3 Global Metabolic Syndrome Market Size, By Protein, By Value, 2018H-2028F (USD Million & CAGR)
  3.7.4 Global Metabolic Syndrome Market Size, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)
  3.7.5 Global Metabolic Syndrome Market Size, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)
  3.8 Global Metabolic Syndrome Market Segmentation: By Route of Administration
  3.8.1 Global Metabolic Syndrome Market, By Route of Administration Overview
  3.8.2 Global Metabolic Syndrome Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
  3.8.3 Global Metabolic Syndrome Market Size, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)
  3.8.4 Global Metabolic Syndrome Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)

  4. Global Metabolic Syndrome Market, Region Analysis
  4.1 Regional Coverage of the Study

  5. Americas Metabolic Syndrome Market: Historic and Forecast (2018-2028)
  5.1 Americas Metabolic Syndrome Market: Snapshot
  5.2 Americas Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  5.3 Americas Metabolic Syndrome Market: Key Factors
  5.4 Americas Metabolic Syndrome Market Segmentation: By Indication
  5.4.1 Americas Metabolic Syndrome Market, By Indication Overview
  5.4.2 Americas Metabolic Syndrome Market Size, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  5.4.3 Americas Metabolic Syndrome Market Size, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)
  5.4.4 Americas Metabolic Syndrome Market Size, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  5.4.5 Americas Metabolic Syndrome Market Size, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)
  5.4.6 Americas Metabolic Syndrome Market Size, By Other Indications, By Value, 2018H-2028F (USD Million & CAGR)
  5.5 Americas Metabolic Syndrome Market Segmentation: By Molecule Type
  5.5.1 Americas Metabolic Syndrome Market, By Molecule Type Overview
  5.5.2 Americas Metabolic Syndrome Market Size, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)
  5.5.3 Americas Metabolic Syndrome Market Size, By Protein, By Value, 2018H-2028F (USD Million & CAGR)
  5.5.4 Americas Metabolic Syndrome Market Size, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)
  5.5.5 Americas Metabolic Syndrome Market Size, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)
  5.6 Americas Metabolic Syndrome Market Segmentation: By Route of Administration
  5.6.1 Americas Metabolic Syndrome Market, By Route of Administration Overview
  5.6.2 Americas Metabolic Syndrome Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
  5.6.3 Americas Metabolic Syndrome Market Size, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)
  5.6.4 Americas Metabolic Syndrome Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
  5.7 Americas Metabolic Syndrome Market Segmentation: By Country
  5.7.1 United States Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  5.7.1.1 United States Metabolic Syndrome Market, By Indication
  5.7.1.2 United States Metabolic Syndrome Market, By Molecule Type
  5.7.1.3 United States Metabolic Syndrome Market, By Route of Administration
  5.7.2 Canada Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  5.7.2.1 Canada Metabolic Syndrome Market, By Indication
  5.7.2.2 Canada Metabolic Syndrome Market, By Molecule Type
  5.7.2.3 Canada Metabolic Syndrome Market, By Route of Administration
  5.7.3 Rest of Americas Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  5.7.3.1 Rest of Americas Metabolic Syndrome Market, By Indication
  5.7.3.2 Rest of Americas Metabolic Syndrome Market, By Molecule Type
  5.7.3.3 Rest of Americas Metabolic Syndrome Market, By Route of Administration

  6. Europe Metabolic Syndrome Market: Historic and Forecast (2018-2028)
  6.1 Europe Metabolic Syndrome Market: Snapshot
  6.2 Europe Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  6.3 Europe Metabolic Syndrome Market: Key Factors
  6.4 Europe Metabolic Syndrome Market Segmentation: By Indication
  6.4.1 Europe Metabolic Syndrome Market, By Indication Overview
  6.4.2 Europe Metabolic Syndrome Market Size, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  6.4.3 Europe Metabolic Syndrome Market Size, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)
  6.4.4 Europe Metabolic Syndrome Market Size, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  6.4.5 Europe Metabolic Syndrome Market Size, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)
  6.4.6 Europe Metabolic Syndrome Market Size, By Other Indications, By Value, 2018H-2028F (USD Million & CAGR)
  6.5 Europe Metabolic Syndrome Market Segmentation: By Molecule Type
  6.5.1 Europe Metabolic Syndrome Market, By Molecule Type Overview
  6.5.2 Europe Metabolic Syndrome Market Size, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)
  6.5.3 Europe Metabolic Syndrome Market Size, By Protein, By Value, 2018H-2028F (USD Million & CAGR)
  6.5.4 Europe Metabolic Syndrome Market Size, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)
  6.5.5 Europe Metabolic Syndrome Market Size, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)
  6.6 Europe Metabolic Syndrome Market Segmentation: By Route of Administration
  6.6.1 Europe Metabolic Syndrome Market, By Route of Administration Overview
  6.6.2 Europe Metabolic Syndrome Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
  6.6.3 Europe Metabolic Syndrome Market Size, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)
  6.6.4 Europe Metabolic Syndrome Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
  6.7 Europe Metabolic Syndrome Market Segmentation: By Country
  6.7.1 France Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  6.7.1.1 France Metabolic Syndrome Market, By Indication
  6.7.1.2 France Metabolic Syndrome Market, By Molecule Type
  6.7.1.3 France Metabolic Syndrome Market, By Route of Administration
  6.7.2 United Kingdom Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  6.7.2.1 United Kingdom Metabolic Syndrome Market, By Indication
  6.7.2.2 United Kingdom Metabolic Syndrome Market, By Molecule Type
  6.7.2.3 United Kingdom Metabolic Syndrome Market, By Route of Administration
  6.7.3 Italy Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  6.7.3.1 Italy Metabolic Syndrome Market, By Indication
  6.7.3.2 Italy Metabolic Syndrome Market, By Molecule Type
  6.7.3.3 Italy Metabolic Syndrome Market, By Route of Administration
  6.7.4 Spain Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  6.7.4.1 Spain Metabolic Syndrome Market, By Indication
  6.7.4.2 Spain Metabolic Syndrome Market, By Molecule Type
  6.7.4.3 Spain Metabolic Syndrome Market, By Route of Administration
  6.7.5 Germany Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  6.7.5.1 Germany Metabolic Syndrome Market, By Indication
  6.7.5.2 Germany Metabolic Syndrome Market, By Molecule Type
  6.7.5.3 Germany Metabolic Syndrome Market, By Route of Administration
  6.7.6 Rest of Europe Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  6.7.6.1 Rest of Europe Metabolic Syndrome Market, By Indication
  6.7.6.2 Rest of Europe Metabolic Syndrome Market, By Molecule Type
  6.7.6.3 Rest of Europe Metabolic Syndrome Market, By Route of Administration

  7. Asia-Pacific Metabolic Syndrome Market: Historic and Forecast (2018-2028)
  7.1 Asia-Pacific Metabolic Syndrome Market: Snapshot
  7.2 Asia-Pacific Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  7.3 Asia-Pacific Metabolic Syndrome Market: Key Factors
  7.4 Asia-Pacific Metabolic Syndrome Market Segmentation: By Indication
  7.4.1 Asia-Pacific Metabolic Syndrome Market, By Indication Overview
  7.4.2 Asia-Pacific Metabolic Syndrome Market Size, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  7.4.3 Asia-Pacific Metabolic Syndrome Market Size, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)
  7.4.4 Asia-Pacific Metabolic Syndrome Market Size, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  7.4.5 Asia-Pacific Metabolic Syndrome Market Size, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)
  7.4.6 Asia-Pacific Metabolic Syndrome Market Size, By Other Indications, By Value, 2018H-2028F (USD Million & CAGR)
  7.5 Asia-Pacific Metabolic Syndrome Market Segmentation: By Molecule Type
  7.5.1 Asia-Pacific Metabolic Syndrome Market, By Molecule Type Overview
  7.5.2 Asia-Pacific Metabolic Syndrome Market Size, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)
  7.5.3 Asia-Pacific Metabolic Syndrome Market Size, By Protein, By Value, 2018H-2028F (USD Million & CAGR)
  7.5.4 Asia-Pacific Metabolic Syndrome Market Size, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)
  7.5.5 Asia-Pacific Metabolic Syndrome Market Size, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)
  7.6 Asia-Pacific Metabolic Syndrome Market Segmentation: By Route of Administration
  7.6.1 Asia-Pacific Metabolic Syndrome Market, By Route of Administration Overview
  7.6.2 Asia-Pacific Metabolic Syndrome Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
  7.6.3 Asia-Pacific Metabolic Syndrome Market Size, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)
  7.6.4 Asia-Pacific Metabolic Syndrome Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
  7.7 Asia-Pacific Metabolic Syndrome Market Segmentation: By Country
  7.7.1 China Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  7.7.1.1 China Metabolic Syndrome Market, By Indication
  7.7.1.2 China Metabolic Syndrome Market, By Molecule Type
  7.7.1.3 China Metabolic Syndrome Market, By Route of Administration
  7.7.2 Japan Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  7.7.2.1 Japan Metabolic Syndrome Market, By Indication
  7.7.2.2 Japan Metabolic Syndrome Market, By Molecule Type
  7.7.2.3 Japan Metabolic Syndrome Market, By Route of Administration
  7.7.3 India Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  7.7.3.1 India Metabolic Syndrome Market, By Indication
  7.7.3.2 India Metabolic Syndrome Market, By Molecule Type
  7.7.3.3 India Metabolic Syndrome Market, By Route of Administration
  7.7.4 Rest of Asia-Pacific Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  7.7.4.1 Rest of Asia-Pacific Metabolic Syndrome Market, By Indication
  7.7.4.2 Rest of Asia-Pacific Metabolic Syndrome Market, By Molecule Type
  7.7.4.3 Rest of Asia-Pacific Metabolic Syndrome Market, By Route of Administration

  8. Middle-East & Africa Metabolic Syndrome Market: Historic and Forecast (2018-2028)
  8.1 Middle-East & Africa Metabolic Syndrome Market: Snapshot
  8.2 Middle-East & Africa Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  8.3 Middle-East & Africa Metabolic Syndrome Market: Key Factors
  8.4 Middle-East & Africa Metabolic Syndrome Market Segmentation: By Indication
  8.4.1 Middle-East & Africa Metabolic Syndrome Market, By Indication Overview
  8.4.2 Middle-East & Africa Metabolic Syndrome Market Size, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  8.4.3 Middle-East & Africa Metabolic Syndrome Market Size, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)
  8.4.4 Middle-East & Africa Metabolic Syndrome Market Size, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  8.4.5 Middle-East & Africa Metabolic Syndrome Market Size, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)
  8.4.6 Middle-East & Africa Metabolic Syndrome Market Size, By Other Indications, By Value, 2018H-2028F (USD Million & CAGR)
  8.5 Middle-East & Africa Metabolic Syndrome Market Segmentation: By Indication
  8.5.1 Middle-East & Africa Metabolic Syndrome Market, By Indication Overview
  8.5.2 Middle-East & Africa Metabolic Syndrome Market Size, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)
  8.5.3 Middle-East & Africa Metabolic Syndrome Market Size, By Protein, By Value, 2018H-2028F (USD Million & CAGR)
  8.5.4 Middle-East & Africa Metabolic Syndrome Market Size, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)
  8.5.5 Middle-East & Africa Metabolic Syndrome Market Size, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)
  8.6 Middle-East & Africa Metabolic Syndrome Market Segmentation: By Route of Administration
  8.6.1 Middle-East & Africa Metabolic Syndrome Market, By Route of Administration Overview
  8.6.2 Middle-East & Africa Metabolic Syndrome Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
  8.6.3 Middle-East & Africa Metabolic Syndrome Market Size, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)
  8.6.4 Middle-East & Africa Metabolic Syndrome Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)

  9. Market Dynamics
  9.1 Impact Assessment of Market Dynamics on the Global Metabolic Syndrome Market
  9.2 Drivers
  9.3 Restraints
  9.4 Trends

  10. Industry Ecosystem Analysis
  10.1 Macro-Economic Factor Assessment
  10.3 Porter’s Five Forces Model

  11. Competitive Positioning
  11.1 Companies’ Product Positioning
  11.2 Market Position Matrix
  11.3 Market Share Analysis of Metabolic Syndrome Market
  11.4 Company Profiles
  11.4.1 Novo Nordisk
  11.4.2 Eli Lilly and Company
  11.4.3 Takeda Pharmaceutical
  11.4.4 Sanofi
  11.4.5 AstraZeneca
  11.4.6 Amgen
  11.4.7 Merck Co., Inc.
  11.4.8 Johnson & Johnson
  11.4.9 Pfizer
  11.4.10 Abbott

  List of Figures
  Figure 1: Global obesity statistics 2022
  Figure 2: Top marketed Therapeutics by NPV, USDm
  Figure 3: Top Metabolic syndrome pipeline Therapeutics by NPV, USDm
  Figure 4: Global Metabolic Syndrome Market Size, By Value, 2018-2022 (USD Million)
  Figure 5: Global Metabolic Syndrome Market Size, By Value, 2023-2028 (USD Million)
  Figure 6: Global Metabolic Syndrome Market Share, By Indication, 2028 (%)
  Figure 7: Global Metabolic Syndrome Market Size, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 8: Global Metabolic Syndrome Market Absolute Opportunity, By Insulin Resistance Syndrome, 2018-2028 (USD Million)
  Figure 9: Global Metabolic Syndrome Market Size, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 10: Global Metabolic Syndrome Market Absolute Opportunity, By Hypercholesterolemia, 2018-2028 (USD Million)
  Figure 11: Global Metabolic Syndrome Market Size, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 12: Global Metabolic Syndrome Market Absolute Opportunity, By Obesity Syndrome, 2018-2028 (USD Million)
  Figure 13: Global Metabolic Syndrome Market Size, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 14: Global Metabolic Syndrome Market Absolute Opportunity, By Nonalcoholic steatohepatitis, 2018-2028 (USD Million)
  Figure 15: Global Metabolic Syndrome Market Size, By Other Indications, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 16: Global Metabolic Syndrome Market Absolute Opportunity, By Other Indications, 2018-2028 (USD Million)
  Figure 17: Global Metabolic Syndrome Market Size, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 18: Global Metabolic Syndrome Market Absolute Opportunity, By Small Molecule, 2018-2028 (USD Million)
  Figure 19: Global Metabolic Syndrome Market Size, By Protein, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 20: Global Metabolic Syndrome Market Absolute Opportunity, By Protein, 2018-2028 (USD Million)
  Figure 21: Global Metabolic Syndrome Market Size, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 22: Global Metabolic Syndrome Market Absolute Opportunity, By RNA/DNA, 2018-2028 (USD Million)
  Figure 23: Global Metabolic Syndrome Market Size, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 24: Global Metabolic Syndrome Market Absolute Opportunity, By Other Molecules, 2018-2028 (USD Million)
  Figure 25: Global Metabolic Syndrome Market Size, By Oral , By Value, 2018H-2028F (USD Million & CAGR)
  Figure 26: Global Metabolic Syndrome Market Absolute Opportunity, By Oral, 2018-2028 (USD Million)
  Figure 27: Global Metabolic Syndrome Market Size, By Subcutaneous ,By Value, 2018H-2028F (USD Million & CAGR)
  Figure 28: Global Metabolic Syndrome Market Absolute Opportunity, By Subcutaneous, 2018-2028 (USD Million)
  Figure 29: Global Metabolic Syndrome Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 30: Global Metabolic Syndrome Market Absolute Opportunity, By Other ROA, 2018-2028 (USD Million)
  Figure 31: Americas Metabolic Syndrome Market Size, By Value, 2018H-2028F (USD Million)
  Figure 32: Americas Metabolic Syndrome Market Share, By Indication, 2022 (%)
  Figure 33: Americas Metabolic Syndrome Market, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 34: Americas Metabolic Syndrome Market, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 35: Americas Metabolic Syndrome Market, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 36: Americas Metabolic Syndrome Market, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 37: Americas Metabolic Syndrome Market, By Other Indication, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 38: Americas Metabolic Syndrome Market, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 39: Americas Metabolic Syndrome Market, By Protein, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 40: Americas Metabolic Syndrome Market, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 41: Americas Metabolic Syndrome Market, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 42: Americas Metabolic Syndrome Market, By Oral , By Value, 2018H-2028F (USD Million & CAGR)
  Figure 43: Americas Metabolic Syndrome Market, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 44: Americas Metabolic Syndrome Market, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 45: United States Metabolic Syndrome Market, By Value, 2018-2028 (USD Million & CAGR)
  Figure 46: United States Metabolic Syndrome Market Share, By Indication, By 2022 (USD Million)
  Figure 47: United States Metabolic Syndrome Market Share, By Indication Type, By Value, 2022 (%)
  Figure 48: United States Metabolic Syndrome Market Share, By Molecule Type, By Value, 2022 (%)
  Figure 49: United States Metabolic Syndrome Market Share, By Route of Administration, By Value, 2022 (%)
  Figure 50: Canada Metabolic Syndrome Market, By Value, 2018-2028 (USD Million & CAGR)
  Figure 51: Canada Metabolic Syndrome Market Value, By Indication, 2022 (USD Million)
  Figure 52: Canada Metabolic Syndrome Market Share, By Indication, By Value, 2022 (%)
  Figure 53: Canada Metabolic Syndrome Market Share, By Molecule Type, By Value, 2022 (%)
  Figure 54: Canada Metabolic Syndrome Market Share, By Route of Administration, By Value, 2022 (%)
  Figure 55: Rest of Americas Metabolic Syndrome Market, By Value, 2018-2028 (USD Million & CAGR)
  Figure 56: Rest of Americas Metabolic Syndrome Market Value, By Indication, 2022 (USD Million)
  Figure 57: Rest of Americas Metabolic Syndrome Market Share, By Indication, By Value, 2022 (%)
  Figure 58: Rest of Americas Metabolic Syndrome Market Share, By Molecule Type, By Value, 2022 (%)
  Figure 59: Rest of Americas Metabolic Syndrome Market Share, By Route of Administration, By Value, 2022 (%)
  Figure 60: Europe Metabolic Syndrome Market Size, By Value, 2018H-2028F (USD Million)
  Figure 61: Europe Metabolic Syndrome Market Share, By Indication, 2022 (%)
  Figure 62: Europe Metabolic Syndrome Market, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 63: Europe Metabolic Syndrome Market, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 64: Europe Metabolic Syndrome Market, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 65: Europe Metabolic Syndrome Market, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 66: Europe Metabolic Syndrome Market, By Other Indication, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 67: Europe Metabolic Syndrome Market, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 68: Europe Metabolic Syndrome Market, By Protein, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 69: Europe Metabolic Syndrome Market, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 70: Europe Metabolic Syndrome Market, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 71: Europe Metabolic Syndrome Market, By Oral , By Value, 2018H-2028F (USD Million & CAGR)
  Figure 72: Europe Metabolic Syndrome Market, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 73: Europe Metabolic Syndrome Market, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 74: France Metabolic Syndrome Market, By Value, 2018-2028 (USD Million & CAGR)
  Figure 75: France Metabolic Syndrome Market Value, By Indication, 2022 (USD Million)
  Figure 76: France Metabolic Syndrome Market Share, By Indication, By Value, 2022 (%)
  Figure 77: France Metabolic Syndrome Market Share, By Molecule Type, By Value, 2022 (%)
  Figure 78: France Metabolic Syndrome Market Share, By Route of Administration, By Value, 2022 (%)
  Figure 79: United Kingdom Metabolic Syndrome Market, By Value, 2018-2028 (USD Million & CAGR)
  Figure 80: United Kingdom Metabolic Syndrome Market Value, By Indication, 2022 (USD Million)
  Figure 81: United Kingdom Metabolic Syndrome Market Share, By Indication, By Value, 2022 (%)
  Figure 82: United Kingdom Metabolic Syndrome Market Share, By Molecule Type, By Value, 2022 (%)
  Figure 83: United Kingdom Metabolic Syndrome Market Share, By Route of Administration, By Value, 2022 (%)
  Figure 84: Italy Metabolic Syndrome Market, By Value, 2018-2028 (USD Million & CAGR)
  Figure 85: Italy Metabolic Syndrome Market Value, By Indication, 2022 (USD Million)
  Figure 86: Italy Metabolic Syndrome Market Share, By Indication, By Value, 2022 (%)
  Figure 87: Italy Metabolic Syndrome Market Share, By Molecule Type, By Value, 2022 (%)
  Figure 88: Italy Metabolic Syndrome Market Share, By Route of Administration, By Value, 2022 (%)
  Figure 89: Spain Metabolic Syndrome Market, By Value, 2018-2028 (USD Million & CAGR)
  Figure 90: Spain Metabolic Syndrome Market Value, By Indication, 2022 (USD Million)
  Figure 91: Spain Metabolic Syndrome Market Share, By Indication, By Value, 2022 (%)
  Figure 92: Spain Metabolic Syndrome Market Share, By Molecule Type, By Value, 2022 (%)
  Figure 93: Spain Metabolic Syndrome Market Share, By Route of Administration, By Value, 2022 (%)
  Figure 94: Germany Metabolic Syndrome Market, By Value, 2018-2028 (USD Million & CAGR)
  Figure 95: Germany Metabolic Syndrome Market Value, By Indication, 2022 (USD Million)
  Figure 96: Germany Metabolic Syndrome Market Share, By Indication, By Value, 2022 (%)
  Figure 97: Germany Metabolic Syndrome Market Share, By Molecule Type, By Value, 2022 (%)
  Figure 98: Germany Metabolic Syndrome Market Share, By Route of Administration, By Value, 2022 (%)
  Figure 99: Rest of Europe Metabolic Syndrome Market, By Value, 2018-2028 (USD Million & CAGR)
  Figure 100: Rest of Europe Metabolic Syndrome Market Value, By Indication, 2022 (USD Million)
  Figure 101: Rest of Europe Metabolic Syndrome Market Share, By Indication, By Value, 2022 (%)
  Figure 102: Rest of Europe Metabolic Syndrome Market Share, By Molecule Type, By Value, 2022 (%)
  Figure 103: Rest of Europe Metabolic Syndrome Market Share, By Route of Administration, By Value, 2022 (%)
  Figure 104: Asia Pacific Metabolic Syndrome Market Size, By Value, 2018H-2028F (USD Million)
  Figure 105: Asia Pacific Metabolic Syndrome Market Share, By Indication, 2022 (%)
  Figure 106: Asia Pacific Metabolic Syndrome Market, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 107: Asia Pacific Metabolic Syndrome Market, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 108: Asia Pacific Metabolic Syndrome Market, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 109: Asia Pacific Metabolic Syndrome Market, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 110: Asia Pacific Metabolic Syndrome Market, By Other Indication, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 111: Asia Pacific Metabolic Syndrome Market, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 112: Asia Pacific Metabolic Syndrome Market, By Protein, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 113: Asia Pacific Metabolic Syndrome Market, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 114: Asia Pacific Metabolic Syndrome Market, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 115: Asia Pacific Metabolic Syndrome Market, By Oral , By Value, 2018H-2028F (USD Million & CAGR)
  Figure 116: Asia Pacific Metabolic Syndrome Market, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 117: Asia Pacific Metabolic Syndrome Market, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 118: China Metabolic Syndrome Market, By Value, 2018-2028 (USD Million & CAGR)
  Figure 119: China Metabolic Syndrome Market Value, By Indication, 2022 (USD Million)
  Figure 120: China Metabolic Syndrome Market Share, By Indication, By Value, 2022 (%)
  Figure 121: China Metabolic Syndrome Market Share, By Molecule Type, By Value, 2022 (%)
  Figure 122: China Metabolic Syndrome Market Share, By Route of Administration, By Value, 2022 (%)
  Figure 123: Japan Metabolic Syndrome Market, By Value, 2018-2028 (USD Million & CAGR)
  Figure 124: Japan Metabolic Syndrome Market Value, By Indication, 2022 (USD Million)
  Figure 125: Japan Metabolic Syndrome Market Share, By Indication, By Value, 2022 (%)
  Figure 126: Japan Metabolic Syndrome Market Share, By Molecule Type, By Value, 2022 (%)
  Figure 127: Japan Metabolic Syndrome Market Share, By Route of Administration, By Value, 2022 (%)
  Figure 128: India Metabolic Syndrome Market, By Value, 2018-2028 (USD Million & CAGR)
  Figure 129: India Metabolic Syndrome Market Value, By Indication, 2022 (USD Million)
  Figure 130 India Metabolic Syndrome Market Share, By Indication, By Value, 2022 (%)
  Figure 131 India Metabolic Syndrome Market Share, By Molecule Type, By Value, 2022 (%)
  Figure 132: India Metabolic Syndrome Market Share, By Route of Administration, By Value, 2022 (%)
  Figure 133: Rest of Asia Pacific Metabolic Syndrome Market, By Value, 2018-2028 (USD Million & CAGR)
  Figure 134: Rest of Asia Pacific Metabolic Syndrome Market Value, By Indication, 2022 (USD Million)
  Figure 135: Rest of Asia Pacific Metabolic Syndrome Market Share, By Indication, By Value, 2022 (%)
  Figure 136: Rest of Asia Pacific Metabolic Syndrome Market Share, By Molecule Type, By Value, 2022 (%)
  Figure 137: Rest of Asia Pacific Metabolic Syndrome Market Share, By Route of Administration, By Value, 2022 (%)
  Figure 138: Middle East & Africa Metabolic Syndrome Market Size, By Value, 2018H-2028F (USD Million)
  Figure 139: Middle East & Africa Metabolic Syndrome Market Share, By Indication, 2022 (%)
  Figure 140: Middle East & Africa Metabolic Syndrome Market, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 141: Middle East & Africa Metabolic Syndrome Market, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 142: Middle East & Africa Metabolic Syndrome Market, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 143: Middle East & Africa Metabolic Syndrome Market, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 144: Middle East & Africa Metabolic Syndrome Market, By Other Indication, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 145: Middle East & Africa Metabolic Syndrome Market, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 146: Middle East & Africa Metabolic Syndrome Market, By Protein, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 147: Middle East & Africa Metabolic Syndrome Market, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 148: Middle East & Africa Metabolic Syndrome Market, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 149: Middle East & Africa Metabolic Syndrome Market, By Oral , By Value, 2018H-2028F (USD Million & CAGR)
  Figure 150: Middle East & Africa Metabolic Syndrome Market, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 151: Middle East & Africa Metabolic Syndrome Market, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
  Figure 152: Global Impact of Drivers and Restraints
  Figure 153: Market Share of Leading Companies in Metabolic Syndrome Market, 2022E (%)
  Figure 154: Novo Nordisk Revenues, 2020-2022 (USD Million)
  Figure 155: Novo Nordisk Revenues, By Geographic Segments, 2022 (%)
  Figure 156: Novo Nordisk Revenue , By Therapeutic Area, 2022 (%)
  Figure 157: Eli Lilly and Company Revenues, 2020-2022 (USD Million)
  Figure 158: Eli Lilly and Company Revenues, By Geographic Segments, 2022 (%)
  Figure 159: Eli Lilly and Company Revenue , By Therapeutic Area, 2022 (%)
  Figure 160: Takeda Pharmaceuticals Revenues, 2019-2021 (USD Million)
  Figure 161: Takeda Pharmaceuticals Revenues, By Geographic Segments, 2021 (%)
  Figure 162: Takeda Pharmaceuticals Revenue , By Business Segments, 2021 (%)
  Figure 163: Sanofi Revenues, 2020-2022 (USD Million)
  Figure 164: Sanofi Revenues, By Geographic Segments, 2022 (%)
  Figure 165: Sanofi Revenue , By Business Segments, 2022 (%)
  Figure 166: AstraZeneca PLC Revenues, 2020-2022 (USD Million)
  Figure 167: AstraZeneca PLC Revenues, By Geographic Segments, 2022 (%)
  Figure 168: AstraZeneca PLC Revenue , By Business Segments, 2022 (%)
  Figure 169: Amgen, Inc. Revenues, 2020-2022 (USD Million)
  Figure 170: Amgen, Inc. Revenues, By Geographic Segments, 2022 (%)
  Figure 171: Amgen, Inc. Revenue , By Products, 2022 (%)
  Figure 172: Merck & Co., Inc. Revenues, 2020-2022 (USD Million)
  Figure 173: Merck & Co., Inc. Revenues, By Geographic Segments, 2022 (%)
  Figure 174: Merck & Co., Inc. Revenue , By Business Segments, 2022 (%)
  Figure 175: Johnson & Johnson Revenues, 2020-2022 (USD Million)
  Figure 176: Johnson & Johnson Revenues, By Geographic Segments, 2022 (%)
  Figure 177: Johnson & Johnson Revenue , By Business Segments, 2022 (%)
  Figure 178: Pfizer Revenues, 2020-2022 (USD Million)
  Figure 179: Pfizer Revenues, By Business Segments, 2022 (%)
  Figure 180: Pfizer Inc. Revenue , By Geographical Segments, 2022 (%)
  Figure 181: Abbott Laboratories Revenues, 2020-2022 (USD Million)
  Figure 182: Abbott Laboratories Revenues, By Geographic Segments, 2022 (%)
  Figure 183: Abbott Laboratories Revenue , By Business Segments, 2022 (%)
  Figure 177: Johnson & Johnson Revenue , By Business Segments, 2022 (%)
  Figure 178: Pfizer Revenues, 2020-2022 (USD Million)
  Figure 179: Pfizer Revenues, By Business Segments, 2022 (%)
  Figure 180: Pfizer Inc. Revenue , By Geographical Segments, 2022 (%)
  Figure 181: Abbott Laboratories Revenues, 2020-2022 (USD Million)
  Figure 182: Abbott Laboratories Revenues, By Geographic Segments, 2022 (%)
  Figure 183: Abbott Laboratories Revenue , By Business Segments, 2022 (%)

  List of Tables
  Table A1: Global Impact of Macro Economic Factors, By Region
  Table A2: Metabolic Syndrome Therapeutics in Pipeline
  Table A3: United States Metabolic Syndrome Market, By Indication, By Value, 2018-2022 (USD Million)
  Table A4: United States Metabolic Syndrome Market, By Indication, By Value, 2023-2028 (USD Million)
  Table A5: United States Metabolic Syndrome Market, By Molecule Type, By Value, 2018-2022 (USD Million)
  Table A6: United States Metabolic Syndrome Market, By Molecule Type, By Value, 2023-2028 (USD Million)
  Table A7: United States Metabolic Syndrome Market, By Route of Administration, By Value, 2018-2022 (USD Million)
  Table A8: United States Metabolic Syndrome Market, By Route of Administration, By Value, 2023-2028 (USD Million)
  Table A9: Canada Metabolic Syndrome Market, By Indication, By Value, 2018-2022 (USD Million)
  Table A10: Canada Metabolic Syndrome Market, By Indication, By Value, 2023-2028 (USD Million)
  Table A11: Canada Metabolic Syndrome Market, By Molecule Type, By Value, 2018-2022 (USD Million)
  Table A12: Canada Metabolic Syndrome Market, By Molecule Type, By Value, 2023-2028 (USD Million)
  Table A13: Canada Metabolic Syndrome Market, By Route of Administration, By Value, 2018-2022 (USD Million)
  Table A14: Canada Metabolic Syndrome Market, By Route of Administration, By Value, 2023-2028 (USD Million)
  Table A15: Rest of Americas Metabolic Syndrome Market, By Indication, By Value, 2018-2022 (USD Million)
  Table A16: Rest of Americas Metabolic Syndrome Market, By Indication, By Value, 2023-2028 (USD Million)
  Table A17: Rest of Americas Metabolic Syndrome Market, By Molecule Type, By Value, 2018-2022 (USD Million)
  Table A18: Rest of Americas Metabolic Syndrome Market, By Molecule Type, By Value, 2023-2028 (USD Million)
  Table A19: Rest of Americas Metabolic Syndrome Market, By Route of Administration, By Value, 2018-2022 (USD Million)
  Table A20: Rest of Americas Metabolic Syndrome Market, By Route of Administration, By Value, 2023-2028 (USD Million)
  Table A21: France Metabolic Syndrome Market, By Indication, By Value, 2018-2022 (USD Million)
  Table A22: France Metabolic Syndrome Market, By Indication, By Value, 2023-2028 (USD Million)
  Table A23: France Metabolic Syndrome Market, By Molecule Type, By Value, 2018-2022 (USD Million)
  Table A24: France Metabolic Syndrome Market, By Molecule Type, By Value, 2023-2028 (USD Million)
  Table A25: France Metabolic Syndrome Market, By Route of Administration, By Value, 2018-2022 (USD Million)
  Table A26: France Metabolic Syndrome Market, By Route of Administration, By Value, 2023-2028 (USD Million)
  Table A27: United Kingdom Metabolic Syndrome Market, By Indication, By Value, 2018-2022 (USD Million)
  Table A28: United Kingdom Metabolic Syndrome Market, By Indication, By Value, 2023-2028 (USD Million)
  Table A29: United Kingdom Metabolic Syndrome Market, By Molecule Type, By Value, 2018-2022 (USD Million)
  Table A30: United Kingdom Metabolic Syndrome Market, By Molecule Type, By Value, 2023-2028 (USD Million)
  Table A31: United Kingdom Metabolic Syndrome Market, By Route of Administration, By Value, 2018-2022 (USD Million)
  Table A32: United Kingdom Metabolic Syndrome Market, By Route of Administration, By Value, 2023-2028 (USD Million)
  Table A33: Italy Metabolic Syndrome Market, By Indication, By Value, 2018-2022 (USD Million)
  Table A34: Italy Metabolic Syndrome Market, By Indication, By Value, 2023-2028 (USD Million)
  Table A35: Italy Metabolic Syndrome Market, By Molecule Type, By Value, 2018-2022 (USD Million)
  Table A36: Italy Metabolic Syndrome Market, By Molecule Type, By Value, 2023-2028 (USD Million)
  Table A37: Italy Metabolic Syndrome Market, By Route of Administration, By Value, 2018-2022 (USD Million)
  Table A38: Italy Metabolic Syndrome Market, By Route of Administration, By Value, 2023-2028 (USD Million)
  Table A39: Spain Metabolic Syndrome Market, By Indication, By Value, 2018-2022 (USD Million)
  Table A40: Spain Metabolic Syndrome Market, By Indication, By Value, 2023-2028 (USD Million)
  Table A41: Spain Metabolic Syndrome Market, By Molecule Type, By Value, 2018-2022 (USD Million)
  Table A42: Spain Metabolic Syndrome Market, By Molecule Type, By Value, 2023-2028 (USD Million)
  Table A43: Spain Metabolic Syndrome Market, By Route of Administration, By Value, 2018-2022 (USD Million)
  Table A44: Spain Metabolic Syndrome Market, By Route of Administration, By Value, 2023-2028 (USD Million)
  Table A45: Germany Metabolic Syndrome Market, By Indication, By Value, 2018-2022 (USD Million)
  Table A46: Germany Metabolic Syndrome Market, By Indication, By Value, 2023-2028 (USD Million)
  Table A47: Germany Metabolic Syndrome Market, By Molecule Type, By Value, 2018-2022 (USD Million)
  Table A48: Germany Metabolic Syndrome Market, By Molecule Type, By Value, 2023-2028 (USD Million)
  Table A49: Germany Metabolic Syndrome Market, By Route of Administration, By Value, 2018-2022 (USD Million)
  Table A50: Germany Metabolic Syndrome Market, By Route of Administration, By Value, 2023-2028 (USD Million)
  Table A51: Rest of Europe Metabolic Syndrome Market, By Indication, By Value, 2018-2022 (USD Million)
  Table A52: Rest of Europe Metabolic Syndrome Market, By Indication, By Value, 2023-2028 (USD Million)
  Table A53: Rest of Europe Metabolic Syndrome Market, By Molecule Type, By Value, 2018-2022 (USD Million)
  Table A54: Rest of Europe Metabolic Syndrome Market, By Molecule Type, By Value, 2023-2028 (USD Million)
  Table A55: Rest of Europe Metabolic Syndrome Market, By Route of Administration, By Value, 2018-2022 (USD Million)
  Table A56: Rest of Europe Metabolic Syndrome Market, By Route of Administration, By Value, 2023-2028 (USD Million)
  Table A57: China Metabolic Syndrome Market, By Indication, By Value, 2018-2022 (USD Million)
  Table A58: China Metabolic Syndrome Market, By Indication, By Value, 2023-2028 (USD Million)
  Table A59: China Metabolic Syndrome Market, By Molecule Type, By Value, 2018-2022 (USD Million)
  Table A60: China Metabolic Syndrome Market, By Molecule Type, By Value, 2023-2028 (USD Million)
  Table A61: China Metabolic Syndrome Market, By Route of Administration, By Value, 2018-2022 (USD Million)
  Table A62: China Metabolic Syndrome Market, By Route of Administration, By Value, 2023-2028 (USD Million)
  Table A63: Japan Metabolic Syndrome Market, By Indication, By Value, 2018-2022 (USD Million)
  Table A64: Japan Metabolic Syndrome Market, By Indication, By Value, 2023-2028 (USD Million)
  Table A65: Japan Metabolic Syndrome Market, By Molecule Type, By Value, 2018-2022 (USD Million)
  Table A66: Japan Metabolic Syndrome Market, By Molecule Type, By Value, 2023-2028 (USD Million)
  Table A67: Japan Metabolic Syndrome Market, By Route of Administration, By Value, 2018-2022 (USD Million)
  Table A68: Japan Metabolic Syndrome Market, By Route of Administration, By Value, 2023-2028 (USD Million)
  Table A69: India Metabolic Syndrome Market, By Indication, By Value, 2018-2022 (USD Million)
  Table A70: India Metabolic Syndrome Market, By Indication, By Value, 2023-2028 (USD Million)
  Table A71: India Metabolic Syndrome Market, By Molecule Type, By Value, 2018-2022 (USD Million)
  Table A72: India Metabolic Syndrome Market, By Molecule Type, By Value, 2023-2028 (USD Million)
  Table A73: India Metabolic Syndrome Market, By Route of Administration, By Value, 2018-2022 (USD Million)
  Table A74: India Metabolic Syndrome Market, By Route of Administration, By Value, 2023-2028 (USD Million)
  Table A75: Rest of Asia Pacific Metabolic Syndrome Market, By Indication, By Value, 2018-2022 (USD Million)
  Table A76: Rest of Asia Pacific Metabolic Syndrome Market, By Indication, By Value, 2023-2028 (USD Million)
  Table A77: Rest of Asia Pacific Metabolic Syndrome Market, By Molecule Type, By Value, 2018-2022 (USD Million)
  Table A78: Rest of Asia Pacific Metabolic Syndrome Market, By Molecule Type, By Value, 2023-2028 (USD Million)
  Table A79: Rest of Asia Pacific Metabolic Syndrome Market, By Route of Administration, By Value, 2018-2022 (USD Million)
  Table A80: Rest of Asia Pacific Metabolic Syndrome Market, By Route of Administration, By Value, 2023-2028 (USD Million)
  Table A81: Novo Nordisk Key Financials, 2020-2022
  Table A82: Eli Lilly and Company Key Financials, 2020-2022
  Table A83: Takeda Pharmaceuticals Key Financials, 2020-2022
  Table A84: Sanofi Key Financials, 2020-2022
  Table A85: AstraZeneca PLC Key Financials, 2020-2022
  Table A86: Amgen, Inc. Key Financials, 2020-2022
  Table A87: Merck & Co., Inc. Key Financials, 2020-2022
  Table A88: Johnson & Johnson Key Financials, 2020-2022
  Table A89: Pfizer Key Financials, 2020-2022
  Table A90: Abbott Laboratories Key Financials, 2020-2022